🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
121

Quick answer

Novartis India has 121 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  2. 00 mg/mL Concentrate for solution for infusion, VHB937

    Novartis Pharmaceuticals

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  3. A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

    Novartis Pharmaceuticals

    Metastatic neuroendocrine prostate cancer

    phase 2 other active

    1 trial

  4. ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  5. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Pharmaceuticals

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  6. ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  7. AMO959, ENZALUTAMIDE, Enzalutamide, Prednison 5 mg GALEN® Tabletten, -, DEGARELIX, RELUGOLIX, Prednison acis 5 mg, Pluvicto 1 000 MBq/mL solution for injection/infusion, ABIRATERONE, Abiraterone, PIFLUFOLASTAT (18F), AMO959, GOZETOTIDE, DEGARELIX

    Novartis Pharmaceuticals

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  8. ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib

    Novartis Pharmaceuticals

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  9. AUY922

    Novartis Pharmaceuticals

    Advanced HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  11. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  12. BGG492

    Novartis Pharmaceuticals

    Adrenocortical Adenoma

    phase 2 small molecule completed

    1 trial

  13. BGJ398

    Novartis Pharmaceuticals

    Recurrent Glioblastoma or Other Glioma Subtypes

    phase 2 small molecule completed

    1 trial

  14. BION-1301 Single Dose

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule active

    1 trial

  15. BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  16. BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  17. Bion 1301/FUB523

    Novartis Pharmaceuticals

    IgA nephropathy

    phase 2 small molecule active

    1 trial

  18. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  19. CPK850

    Novartis Pharmaceuticals

    Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene

    phase 2 small molecule active

    1 trial

  20. CSJ117

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    2 trials

  21. CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS, YTB323, CYCLOPHOSPHAMIDE, RITUXIMAB, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TOCILIZUMAB, RITUXIMAB

    Novartis Pharmaceuticals

    Severe refractory idiopathic inflammatory myopathies (IIM)

    phase 2 small molecule active

    1 trial

  22. CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  23. Canakinumab 150 mg

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  24. Capecitabine

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  25. Ceritinib (LDK378)

    Novartis Pharmaceuticals

    Tumors With Aberrations in ALK

    phase 2 small molecule terminated

    1 trial

  26. DANAZOL , -, -, -, ENTECAVIR , -, VAY736

    Novartis Pharmaceuticals

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 small molecule active

    1 trial

  27. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  28. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  29. DFV890, DFV890, Placebo to MAS825 100 mg/1 mL Solution for Injection, Placebo to DFV890 10 mg and 25 mg film-coated tablet, MAS825

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

  30. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  31. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  32. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  33. Deferasirox

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  34. Deferasirox granule formulation

    Novartis Pharmaceuticals

    Transfusion-dependent Anemia

    phase 2 small molecule completed

    1 trial

  35. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  36. EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  37. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  38. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  39. EYU688

    Novartis Pharmaceuticals

    Dengue

    phase 2 small molecule active

    1 trial

  40. Eltrombopag

    Novartis Pharmaceuticals

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  41. FGF401

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule completed

    1 trial

  42. FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  43. FLUDARABINE PHOSPHATE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, BENDAMUSTINE, PHE885

    Novartis Pharmaceuticals

    Adult patients with relapsed and refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  44. FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  45. FWY003, FWY003, Placebo to FWY003, FWY003

    Novartis Pharmaceuticals

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  46. GHZ339, -, Placebo to GHZ339, -, PIMECROLIMUS , TACROLIMUS , -

    Novartis Pharmaceuticals

    Moderate to severe atopic dermatitis

    phase 2 small molecule active

    1 trial

  47. GIA632

    Novartis Pharmaceuticals

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  48. GIA632, Placebo to GIA632 150 mg/mL solution for injection

    Novartis Pharmaceuticals

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

121 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.